Payers' Guide

Skip to main content

Select Drug Profiles, Payers' Guide

Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy

Select Drug Profiles, Payers' Guide

Kevzara (Sarilumab), a New IL-6 Receptor Antagonist, Approved for Active Rheumatoid Arthritis

Select Drug Profiles, Payers' Guide

Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Gazyva (Obinutuzumab) Approved as First-Line Treatment, with Chemotherapy, for Patients with Follicular Lymphoma

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Dysport (AbobotulinumtoxinA) Now FDA Approved for the Treatment of Lower-Limb Spasticity in Adults

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Dupixent (Dupilumab) First Biologic Drug Approved for Patients with Moderate-to-Severe Atopic Dermatitis

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Bavencio (Avelumab) Approved for Metastatic Merkel-Cell Carcinoma and for Urothelial Carcinoma

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Lisa A. Raedler, PhD, RPh

FDA Approvals, FDA Approvals, Drug Updates, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2016

FDA Approvals, FDA Approvals, Drug Updates, Payers' Guide

Welcome to the Eighth Annual Payers’ Guide to New FDA Approvals

2
3
4
5
6
7
8

Page 5 of 19
Results 41 - 50 of 185